<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-IIR-17010787</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-03-05</date_registration>
      <primary_sponsor>Shanghai General Hospital</primary_sponsor>
      <public_title>Recombinant human thrombopoietin (rhTPO) combined with granulocyte colony stimulating factor (G-CSF) for autologous peripheral blood stem cell morbiliztion, a prospective, randomized, multicentric phase II clinical trial </public_title>
      <acronym />
      <scientific_title>Recombinant human thrombopoietin (rhTPO) combined with granulocyte colony stimulating factor (G-CSF) for autologous peripheral blood stem cell morbiliztion, a prospective, randomized, multicentric phase II clinical trial </scientific_title>
      <Scientific_acronym />
      <date_enrolment>2010-12-31</date_enrolment>
      <type_enrolment />
      <target_size>Experimental group:40;Control Group:38;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=17150</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>II (Phase II study)</phase>
      <hc_freetext>lymphoma for Autologous peripheral blood stem </hc_freetext>
      <i_freetext>Experimental group:With TPO;Control Group:Without TPO;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Haitao Bai</firstname>
        <middlename />
        <lastname />
        <address>100 Haining Road, Hongkou district, Shanghai, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13817548894</telephone>
        <email>13817548894@163.com</email>
        <affiliation>Shanghai General Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Chun Wang</firstname>
        <middlename />
        <lastname />
        <address>100 Haining Road, Hongkou district, Shanghai, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13386259777</telephone>
        <email>wangchunmd@163.com</email>
        <affiliation>Shanghai General Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Patients diagnosed as lymphoma with pathological evidences;
2. Patients that have indications for APBSCT and are willing to have transplantation;
3. Aged 18-60 years;
4. ECOG ≤3
5. Normal organ functions should satisfy: liver function: ALT, AST, TBIL≤ twice of the normal maximum; renal function: BUN, Cr≤1.5 times of the normal maximum; cardiac function: ECG reveals no signs of acute myocardial infarction, arrhythmia, nor II or III degree of a-v blockage; heart function failure should be no more than degree II; no active rheumatic heart diseases;
6. No contraindications for chemotherapy;
7. Patients should sign the written consent before enrollment of the trial, and the written consent should consent all the contents of the trial;
8. Willing to follow the therapeutic plan, the follow-up plan and take the corresponding lab examinations. </inclusion_criteria>
      <agemin>18</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Contra-indications for chemotherapy;
2. Patients with severe organ impairment: including respiratory failure, heart failure of degree II and beyond, decompensated liver failure, renal failure; uncontrolled hypertention or diabetes, severe diabetic retinal disease;
3. Use of cytokines beside G-CSF within 3 weeks prior to enrollment;
4. Uncontrolled infection;
5. History of severe rhTPO allergy;
6. Women during pregnancy or lactation;
7. Patients that are participating other trials;
8. Patients with other severe acute/chronic physical or mental disorders, or with abnormal lab tests that may impair drug administration or influence the researchers evaluation, or influence the explanation about the results.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>nucleated cell count;CD34+ cell count;times needed for collecting required amount of cells;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>compliance rate;excellence rate;implantation time;RBC transfusion amount after implantation;Platelet transfusion amount after implantation;Incidence of infection during transplantation;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-collected</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>